Pacira BioSciences
PCRX
208 hedge funds and large institutions have $1.69B invested in Pacira BioSciences in 2018 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 69 increasing their positions, 76 reducing their positions, and 18 closing their positions.
301% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $7.81M
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
11% more funds holding
Funds holding: 187 → 208 (+21)
9% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 76
1.81% less ownership
Funds ownership: 99.83% → 98.02% (-1.8%)
16% less capital invested
Capital invested by funds: $2.01B → $1.69B (-$325M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$25.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.3M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$14.9M |
| 4 |
Renaissance Technologies
New York
|
+$13.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$106M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$14.8M |
| 3 |
PC
PointState Capital
New York
|
-$12.6M |
| 4 |
Millennium Management
New York
|
-$9.54M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.37M |
PCRX Hedge Fund Activity: Q4 2018 in Review
208 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2018, worth a combined $1.69B — down 16% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PCRX positions and 18 closed out — a net gain of 23 holders — while 69 added to existing stakes and 76 trimmed.
The largest buyer was HealthCor Management, adding an estimated $25.8M. The largest seller was PFM Health Sciences, cutting an estimated $106M.
- 208 institutional investors held Pacira BioSciences (PCRX) as of Q4 2018, up from 187 in Q3 2018.
- Funds reported $1.69B of Pacira BioSciences stock for Q4 2018, down 16% quarter-over-quarter.
- 41 funds opened new Pacira BioSciences positions in Q4 2018 and 18 closed out, a net change of +23 holders.
- The largest Pacira BioSciences buyer in Q4 2018 was HealthCor Management, an estimated $25.8M added.
- The largest Pacira BioSciences seller in Q4 2018 was PFM Health Sciences, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2018.